title: Phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate in dogs with naturally occurring malignant tumors.
abstract: OBJECTIVE To conduct a phase I-II clinical trial of hyaluronan-cisplatin nanoconjugate (HA-Pt) in dogs with naturally occurring malignant tumors. ANIMALS 18 healthy rats, 9 healthy mice, and 16 dogs with cancer. PROCEDURES HA-Pt was prepared and tested by inductively coupled plasma mass spectrometry; DNA-platinum adduct formation and antiproliferation effects of cisplatin and HA-Pt were compared in vitro. Effects of cisplatin (IV) and HA-Pt (SC) in rodents were tested by clinicopathologic assays. In the clinical trial, dogs with cancer received 1 to 4 injections of HA-Pt (10 to 30 mg/m(2), intratumoral or peritumoral, q 3 wk). Blood samples were collected for pharmacokinetic analysis; CBC, serum BUN and creatinine concentration measurement, and urinalysis were conducted before and 1 week after each treatment. Some dogs underwent hepatic enzyme testing. Tumors were measured before the first treatment and 3 weeks after each treatment to assess response. RESULTS No adverse drug effects were detected in pretrial assessments in rodents. Seven of 16 dogs completed the study; 3 had complete tumor responses, 3 had stable disease, and 1 had progressive disease. Three of 7 dogs with oral and nasal squamous cell carcinoma (SCC) that completed the study had complete responses. Myelosuppression and cardiotoxicosis were identified in 6 and 2 dogs, respectively; none had nephrotoxicosis. Four of 5 dogs with hepatic enzymes assessed had increased ALT activities, attributed to diaquated cisplatin products in the HA-Pt. Pharmacokinetic data fit a 3-compartment model. CONCLUSIONS AND CLINICAL RELEVANCE HA-Pt treatment resulted in positive tumor responses in some dogs, primarily those with SCC. The adverse effect rate was high. IMPACT FOR HUMAN MEDICINE Oral SCC in dogs has characteristics similar to human head and neck SCC; these results could be useful in developing human treatments.
authors: Shuang
authors: S
authors: Cai
authors: Ti
authors: T
authors: Zhang
authors: W C
authors: WC
authors: Forrest
authors: Qiuhong
authors: Q
authors: Yang
authors: Chad
authors: C
authors: Groer
authors: Eva
authors: E
authors: Mohr
authors: Daniel J
authors: DJ
authors: Aires
authors: Sandra M
authors: SM
authors: Axiak-Bechtel
authors: Brian K
authors: BK
authors: Flesner
authors: Carolyn J
authors: CJ
authors: Henry
authors: Kimberly A
authors: KA
authors: Selting
authors: Deborah
authors: D
authors: Tate
authors: Jeffrey A
authors: JA
authors: Swarz
authors: Jeffrey N
authors: JN
authors: Bryan
authors: M Laird
authors: ML
authors: Forrest
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002945:Cisplatin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D005260:Female; D006820:Hyaluronic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D058726:Nanoconjugates / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy / Q000662:veterinary*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012074:Remission Induction
chemical_list: D000970:Antineoplastic Agents; D058726:Nanoconjugates; D006820:Hyaluronic Acid; D002945:Cisplatin